SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Halicka Dorota))
 

Sökning: (WFRF:(Halicka Dorota)) > Broad targeting of ...

  • Wang, ZongweiDepartment of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA (författare)

Broad targeting of angiogenesis for cancer prevention and therapy

  • Artikel/kapitelEngelska2015

Förlag, utgivningsår, omfång ...

  • Elsevier,2015
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-115783
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-115783URI
  • https://doi.org/10.1016/j.semcancer.2015.01.001DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:132616664URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:for swepub-publicationtype

Anmärkningar

  • Funding agencies: Swedish Society for Medical Research; Goesta Fraenkel Foundation; Ake Wibergs Foundation; Ollie och Elof Ericssons Foundation; Karolinska Institute; Linkoping University; University of Glasgow; Beatson Oncology Center Fund; Cancer Research UK grant
  • Deregulation of angiogenesis - the growth of new blood vessels from an existing vasculature - is a main driving force in many severe human diseases including cancer. As such, tumor angiogenesis is important for delivering oxygen and nutrients to growing tumors, and therefore considered an essential pathologic feature of cancer, while also playing a key role in enabling other aspects of tumor pathology such as metabolic deregulation and tumor dissemination/metastasis. Recently, inhibition of tumor angiogenesis has become a clinical anti-cancer strategy in line with chemotherapy, radiotherapy and surgery, which underscore the critical importance of the angiogenic switch during early tumor development. Unfortunately the clinically approved anti-angiogenic drugs in use today are only effective in a subset of the patients, and many who initially respond develop resistance over time. Also, some of the anti-angiogenic drugs are toxic and it would be of great importance to identify alternative compounds, which could overcome these drawbacks and limitations of the currently available therapy. Finding "the most important target" may, however, prove a very challenging approach as the tumor environment is highly diverse, consisting of many different cell types, all of which may contribute to tumor angiogenesis. Furthermore, the tumor cells themselves are genetically unstable, leading to a progressive increase in the number of different angiogenic factors produced as the cancer progresses to advanced stages. As an alternative approach to targeted therapy, options to broadly interfere with angiogenic signals by a mixture of non-toxic natural compound with pleiotropic actions were viewed by this team as an opportunity to develop a complementary anti-angiogenesis treatment option. As a part of the "Halifax Project" within the "Getting to know cancer" framework, we have here, based on a thorough review of the literature, identified 10 important aspects of tumor angiogenesis and the pathological tumor vasculature which would be well suited as targets for anti-angiogenic therapy: (1) endothelial cell migration/tip cell formation, (2) structural abnormalities of tumor vessels, (3) hypoxia, (4) lymphangiogenesis, (5) elevated interstitial fluid pressure, (6) poor perfusion, (7) disrupted circadian rhythms, (8) tumor promoting inflammation, (9) tumor promoting fibroblasts and (10) tumor cell metabolism/acidosis. Following this analysis, we scrutinized the available literature on broadly acting anti-angiogenic natural products, with a focus on finding qualitative information on phytochemicals which could inhibit these targets and came up with 10 prototypical phytochemical compounds: (1) oleic acid, (2) tripterine, (3) silibinin, (4) curcumin, (5) epigallocatechin-gallate, (6) kaempferol, (7) melatonin, (8) enterolactone, (9) withaferin A and (10) resveratrol. We suggest that these plant-derived compounds could be combined to constitute a broader acting and more effective inhibitory cocktail at doses that would not be likely to cause excessive toxicity. All the targets and phytochemical approaches were further cross-validated against their effects on other essential tumorigenic pathways (based on the "hallmarks" of cancer) in order to discover possible synergies or potentially harmful interactions, and were found to generally also have positive involvement in/effects on these other aspects of tumor biology. The aim is that this discussion could lead to the selection of combinations of such anti-angiogenic compounds which could be used in potent anti-tumor cocktails, for enhanced therapeutic efficacy, reduced toxicity and circumvention of single-agent anti-angiogenic resistance, as well as for possible use in primary or secondary cancer prevention strategies.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Dabrosin, CharlottaÖstergötlands Läns Landsting,Linköpings universitet,Avdelningen för kliniska vetenskaper,Hälsouniversitetet,Onkologiska kliniken US(Swepub:liu)chada67 (författare)
  • Yin, XinMedicine and Research Services, Veterans Affairs San Diego Healthcare System & University of California, San Diego, San Diego, CA, USA (författare)
  • Fuster, Mark MMedicine and Research Services, Veterans Affairs San Diego Healthcare System & University of California, San Diego, San Diego, CA, USA (författare)
  • Arreola, AlexandraLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA (författare)
  • Rathmell, W KimrynLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA (författare)
  • Generali, DanieleMolecular Therapy and Pharmacogenomics Unit, AO Isituti Ospitalieri di Cremona, Cremona, Italy (författare)
  • Nagaraju, Ganji PDepartment of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA (författare)
  • El-Rayes, BasselDepartment of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA (författare)
  • Ribatti, DomenicoDepartment of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy, National Cancer Institute Giovanni Paolo II, Bari, Italy (författare)
  • Chen, Yi CharlieDepartment of Biology, Alderson Broaddus University, Philippi, WV, USA (författare)
  • Honoki, KanyaDepartment of Orthopedic Surgery, Arthroplasty and Regenerative Medicine, Nara Medical University, Nara, Japan (författare)
  • Fujii, HiromasaDepartment of Orthopedic Surgery, Arthroplasty and Regenerative Medicine, Nara Medical University, Nara, Japan (författare)
  • Georgakilas, Alexandros GPhysics Department, School of Applied Mathematics and Physical Sciences, National Technical University of Athens, Athens, Greece,School of Chemical and Bio Technology, SASTRA University, Thanjavur, India (författare)
  • Nowsheen, SomairaMayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN, USA (författare)
  • Amedei, AmedeoDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy (författare)
  • Niccolai, ElenaDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy (författare)
  • Amin, AmrDepartment of Biology, College of Science, United Arab Emirate University, United Arab EmiratesFaculty of Science, Cairo University, Cairo, Egypt (författare)
  • Ashraf, S SalmanDepartment of Chemistry, College of Science, United Arab Emirate University, United Arab Emirates (författare)
  • Helferich, BillUniversity of Illinois at Urbana Champaign, Urbana, IL, USA (författare)
  • Yang, XujuanUniversity of Illinois at Urbana Champaign, Urbana, IL, USA (författare)
  • Guha, GunjanSchool of Chemical and Bio Technology, SASTRA University, Thanjavur, India (författare)
  • Bhakta, DipitaSchool of Chemical and Bio Technology, SASTRA University, Thanjavur, India (författare)
  • Ciriolo, Maria RosaDepartment of Biology, University of Rome “Tor Vergata”, Rome, Italy (författare)
  • Aquilano, KatiaDepartment of Biology, University of Rome “Tor Vergata”, Rome, Italy (författare)
  • Chen, SophieOvarian and Prostate Cancer Research Trust Laboratory, Guilford, Surrey, UK (författare)
  • Halicka, DorotaNew York Medical College, New York City, NY, USA (författare)
  • Mohammed, Sulma IDepartment of Comparative Pathobiology, Purdue University Center for Cancer Research, West Lafayette, IN, USA (författare)
  • Azmi, Asfar SSchool of Medicine, Wayne State University, Detroit, MI, USA (författare)
  • Bilsland, AlanInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK (författare)
  • Keith, W NicolInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK (författare)
  • Jensen, Lasse DLinköpings universitet,Avdelningen för kardiovaskulär medicin,Hälsouniversitetet,Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden(Swepub:liu)larje86 (författare)
  • Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USAAvdelningen för kliniska vetenskaper (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Seminars in Cancer Biology: ElsevierS1044-579X:15, s. 00002-000041044-579X1096-3650

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy